{
    "root": "5001b104-2557-499d-bf89-0a01149937a9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "TOUJEO",
    "value": "20250312",
    "ingredients": [
        {
            "name": "insulin glargine",
            "code": "2ZM8CX04RZ"
        },
        {
            "name": "zinc",
            "code": "J41CSQ7QDS"
        },
        {
            "name": "metacresol",
            "code": "GGO4Y809LO"
        },
        {
            "name": "glycerin",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "water",
            "code": "059QF0KO0R"
        },
        {
            "name": "METACRESOL",
            "code": "GGO4Y809LO"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "TOUJEO is indicated to improve glycemic control in adults and pediatric patients 6 years of age and older with diabetes mellitus.",
    "contraindications": "Individualize dose based on type of diabetes, metabolic needs, blood glucose monitoring results and glycemic control goal. ( 2.2 ) Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time during the day, at the same time every day. ( 2.1 ) Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. ( 2.1 ) Do not dilute or mix with any other insulin or solution. ( 2.1 ) See Full Prescribing Information for the recommended starting dosage in patients with type 2 diabetes and how to switch to TOUJEO from other insulins ( 2.3 , 2.4 ) Closely monitor glucose when switching to TOUJEO and during initial weeks thereafter. ( 2.4 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "TOUJEO is contraindicated:\n                  \n                     During episodes of hypoglycemia [see Warnings and Precautions (5.3)].\n                     In patients with hypersensitivity to insulin glargine or any excipients in TOUJEO [see Warnings and Precautions (5.5)]."
}